Literature DB >> 20497842

Benign prostatic hyperplasia.

David R Paolone1.   

Abstract

This article reviews the epidemiology of benign prostatic hyperplasia (BPH), evaluation of patients with lower urinary tract symptomatology (LUTS), and management of patients with BPH and LUTS. The evaluation includes history and physical examination, laboratory testing, and specialized studies. The management includes medical and surgical options. Medical options include alpha-1-adrenergic receptor blockers, 5alpha-reductase inhibitors, and combinations of these and other medications. Surgical options include endoscopic procedures, open procedures, and laser procedures. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20497842     DOI: 10.1016/j.cger.2010.02.010

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  15 in total

1.  Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: a randomized controlled trial.

Authors:  Yuan-peng Huang; Yan-hui Wen; Geng-hui Wu; Zhen-feng Hong; Shang-wen Xu; A-xiang Peng
Journal:  Chin J Integr Med       Date:  2014-11-27       Impact factor: 1.978

2.  Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seeds.

Authors:  Chukwunonso E C C Ejike; Lawrence U S Ezeanyika
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-06-01

3.  Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.

Authors:  Erkan Karadağ; Sedat Öner; Yasemin U Budak; Özcan Atahan
Journal:  Int Urol Nephrol       Date:  2011-04-08       Impact factor: 2.370

Review 4.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

5.  Qianliening capsule () inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis.

Authors:  Zhen-Feng Hong; Jiu-Mao Lin; Xiao-Yong Zhong; Ying Li; Jian-Heng Zhou; Wei Xu; Jun Peng
Journal:  Chin J Integr Med       Date:  2012-10-20       Impact factor: 1.978

6.  Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways.

Authors:  Eman M Elbaz; Hebat Allah A Amin; Ahmed S Kamel; Sherehan M Ibrahim; Hebatullah S Helmy
Journal:  Inflammopharmacology       Date:  2020-08-12       Impact factor: 4.473

7.  miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia.

Authors:  Liya Liu; Yun Wan; Aling Shen; Jinyan Zhao; Jiumao Lin; Xiaoyong Zhong; Yuchen Zhang; Zhenfeng Hong
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-30       Impact factor: 2.629

8.  Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia.

Authors:  Su Kang Kim; Joo-Ho Chung; Byung-Cheol Lee; Sang Won Lee; Kang Hyo Lee; Young Ock Kim
Journal:  Int Neurourol J       Date:  2014-12-29       Impact factor: 2.835

9.  Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway.

Authors:  Jiumao Lin; Jianheng Zhou; Wei Xu; Xiaoyong Zhong; Zhenfeng Hong; Jun Peng
Journal:  Exp Ther Med       Date:  2013-03-15       Impact factor: 2.447

10.  Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.

Authors:  Jiumao Lin; Jianheng Zhou; Wei Xu; Zhenfeng Hong; Jun Peng
Journal:  Exp Ther Med       Date:  2014-05-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.